Boehringer nabs FDA's first in­ter­change­abil­i­ty des­ig­na­tion for its Hu­mi­ra com­peti­tor — but will it mat­ter?

The FDA late Fri­day award­ed Boehringer In­gel­heim the first in­ter­change­abil­i­ty des­ig­na­tion for its Hu­mi­ra biosim­i­lar Cyl­te­zo, mean­ing that when it launch­es in Ju­ly 2023, phar­ma­cists …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER